Pediatric asthma: An unmet need for more effective, focused treatments

Abstract

Background Despite remarkable advances in our understanding of asthma, there are still several unmet needs associated with the management of pediatric asthma. Methods A two‐day, face‐to‐face meeting was held in London, United Kingdom, on October 28 and 29, 2017, involving a group of international expert clinicians and scientists in asthma management to discuss the challenges and unmet needs that remain to be addressed in pediatric asthma. Results These unmet needs include a lack of clinical efficacy and safety evidence, and limited availability of non‐steroid‐based alternative therapies in patients <6 years of age. An increased focus on children is needed in the context of clinical practice guidelines for asthma; current pediatric practice relies mostly on extrapolations from adult recommendations. Furthermore, no uniform definition of pediatric asthma exists, which hampers timely and robust diagnosis of the condition in affected patients. Conclusions There is a need for a uniform definition of pediatric asthma, clearly distinguishable from adult asthma. Furthermore, guidelines which provide specific treatment recommendations for the management of pediatric asthma are also needed. Clinical trials and real‐world evidence studies assessing anti‐immunoglobulin E (IgE) therapies and other monoclonal antibodies in children <6 years of age with asthma may provide further information regarding the most appropriate treatment options in these vulnerable patients. Early intervention with anti‐IgE and non‐steroid‐based alternative therapies may delay disease progression, leading to improved clinical outcomes.

How can we minimise the use of regular oral corticosteroids in asthma?

“…This has been reported in real-life omalizumab studies in a large number of children with severe allergic asthma [93,102]. However, these expensive drugs are not available all over the world and also not to preschool children [103]. Because low FEV 1 is associated with OCS use in adults, trajectories of FEV 1 are extremely meaningful for early identification of at-risk patients.…”

Bacteriophage deficiency characterizes respiratory virome dysbiosis in childhood asthma

“…Asthma remains a major driver of morbidity throughout the productive years, while also affecting healthy aging 3 . Asthma susceptibility to viral and bacterial respiratory infections may influence the divergence from a healthy trajectory and is one of the main priorities for research and intervention 1, [4][5][6][7][8] .…”

Prioritizing Research Challenges and Funding for Allergy and Asthma and the Need for Translational Research — The European Strategic Forum on Allergic Diseases

“…1. Внедрение протоколов в клиническую практику, сбор big data, сотрудничество, совместные программы аудита, единые критерии качества -необходимые компоненты улучшения качества оказываемой помощи детям с аллергией и астмой [28][29][30].…”